2 results
Approved WMORecruiting
Primary objectives: • To demonstrate reversal of the antiplatelet effects of ticagrelor after initiation of the intravenous (IV) infusion of PB2452 using the VerifyNow* PRUTest* (VerifyNow*, 2016) platelet function assay in ticagrelor-treated…
Approved WMORecruiting
To compare belzutifan+lenvatinib to cabozantinib with respect to PFS per Response Criteria in Solid Tumors (RECIST) 1.1 as assessedby blinded independent central review (BICR).